Concepedia

Author

Daniele Fagnani

Azienda Ospedaliera di Desio e Vimercate

Also Known As

D Fagnani, D. FAGNANI, D. Fagnani, Daniele Fagnani

42

Publications

1.2K

Citations

13

H-Index

27

Concepts

All Affiliations

Azienda Ospedaliera di Desio e VimercateAzienda Ospedaliera Fatebenefratelli e OftalmicoAzienda Ospedaliera di Valtellina e ValchiavennaLuigi Sacco HospitalOspedale Valduce
DF

About

Daniele Fagnani is an author at Azienda Ospedaliera di Desio e Vimercate specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

97

2

Health Sciences

2

2

34

3

Public Health

1

1

27

4

Gastroenterology

1

1

10

5

Immunology

1

1

13

Daniele Fagnani

×

12

Publications

896

Citations

11

H-Index

YearCitations

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng,

Journal of Clinical Oncology

2020

588

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos,

Clinical Lymphoma Myeloma & Leukemia

2018

89

D-dimer before chemotherapy might predict venous thromboembolism

Guido Arpaia, Monica Carpenedo, Magda Verga,

Blood Coagulation & Fibrinolysis

2009

71

Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis

Daniele Fagnani, Riccardo Franchi, Camillo Porta,

Annals of Oncology

2006

27

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

Maria Giuseppa Vitale, Sarah Scagliarini, Luca Galli,

PLoS ONE

2018

24

Second Line Therapy with Weekly Low-dose Docetaxel for Pretreated Non-Small-Cell Lung Carcinoma Patients: A Multicenter Italian Phase II Study

Antonio Ardizzoia, Mirko Acquati, Daniele Fagnani,

Lung

2004

18

Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations

Gabriella Farina, Flavia Longo, Olga Martelli,

Clinical Lung Cancer

2011

16

Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.

Daniele Fagnani, P. Nova, Clelia Casartelli,

PubMed

2014

14

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)

Monica Ganzinelli, Eliana Rulli, Elisa Caiola,

Scientific Reports

2015

13

Granulocyte Colony-stimulating Factors Used in Clinical Practice: PoloNord Registry-Based Cohort Italian Study

Daniele Fagnani, Luciano Isa, Magda Franca Verga,

Tumori Journal

2014

13

Page 1